首页> 外国专利> PREDICTION OF RADIOTHERAPY RESPONSE FOR PROSTATE CANCER SUBJECT BASED ON IMMUNE DEFENSE RESPONSE GENES

PREDICTION OF RADIOTHERAPY RESPONSE FOR PROSTATE CANCER SUBJECT BASED ON IMMUNE DEFENSE RESPONSE GENES

机译:基于免疫防御响应基因的前列腺癌对策的放射治疗反应预测

摘要

The invention relates to a method of predicting a response of a prostate cancer subject to radiotherapy, comprising determining or receiving the result of a determination of a gene expression profile for each of one or more immune defense response genes selected from the group consisting of: APOBEC3A, AIM2, APOBEC3B, CASP1, CIAO1, CTNNB1, CXCL10, CXCL9, DDX41, DDX58, DDX60, DHX36, DHX58, DHX9, GBP1, HERC5, HIST2H2BE, IFI16, IFI44L, IFIH1, IFIT1, IFIT1B, IFIT2, IFIT3, IFITM1, IFITM3, IL1B, IRF3, IRF5, IRF7, ISG15, ITGAX, LILRB1, LRRFIP1, MAVS, MB21D1, MX1, MX2, MYD88, NLRP3, NOD2, OAS1, OAS3, OASL, OPRK1, POLR3A, PTPRC, PYCARD, RSAD2, STAT1, TBK1, TICAM1, TLR2, TLR3, TLR4, TLR7, TLR8, TLR9, TMEM173, TRIM22, and ZBP1, said gene expression profile(s) being determined in a biological sample obtained from the subject, and determining the prediction of the radiotherapy response based on the gene expression profile(s) for the one or more immune defense response genes.
机译:本发明涉及预测前列腺癌受到放射疗法的响应的方法,包括确定或接收从由以下组成的组中选择的一种或多种免疫防御反应基因的基因表达谱的测定结果。 ,AIM2,APOBEC3B,CASP1,CIAO1,CTNNB1,CXCL10,CXCL9,DDX41,DDX58,DDX60,DHX36,DHX58,DHX9,GBP1,HERC5,HIST2H2BE,IFI16,IFI44L,IFIH1,IFIT1,IFIT1B,IFIT2,IFIT3,IFITM1,IFITM3 ,IL1B,IRF3,IRF5,IRF7,ISG15,ITGAX,LILRB1,LRRFIP1,MAV,MB21D1,MX1,MX2,MYD88,NLRP3,NOD2,OAS1,OAS3,OASL,OPRK1,POLR3A,PTPRC,PYCARD,RSAD2,Stat1,TBK1 ,TiCAM1,TLR2,TLR3,TLR4,TLR7,TLR8,TLR9,TMEM173,TRIM22和ZBP1,所述基因表达谱在从受试者获得的生物样品中测定,并基于的放射疗法响应预测 一种或多种免疫防御反应基因的基因表达谱。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号